%20(1)_edited.jpg)
Cha Therapeutics' mission is to develop proprietary drug combinations and epigenetic therapies to improve patient outcomes in hematologic malignancies like acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), as well as, in breast, solid tumors, and 11 cancers treated with anti PD-L1.
We focus on reprogramming tumor cells, particularly those driven by Wnt signaling, to make them more susceptible to immune checkpoint inhibitors (ICIs) and other immunotherapies.
Our innovative approach aims to trigger the cold-to-hot transition in tumors, enabling ICIs for cancers previously unresponsive to these transformative treatments.
About Us
Meet The Team
Amy S. Yee, Ph.D
Founder & CEO
Dr. Amy S. Yee is the discoverer of the Wnt signaling inhibitor HBP1 and its role in cancer biology, as well as the Wnt-inhibiting properties of the CHA1 compound combination. She has been awarded a preliminary patent for the compound combination, with a full patent filed.
She is also a Professor in the Department of Molecular and Chemical Biology at Tufts Medical School. Dr. Yee is an expert NIH and DOD grant reviewer, journal reviewer, and a highly regarded professor and mentor. Her professional accolades include significant research accomplishments and numerous years of private and government grant support.
K. Eric Paulson, Ph.D.
Co-Founder & President
Dr. K. Eric Paulson is a Research Assistant Professor at Tufts University School of Medicine in the Department of Developmental, Molecular, and Chemical Biology. With over 25 years of research experience at Tufts Medical School, he is an expert in cancer mechanisms and a dedicated contributor to advancing the field.